Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Key Highlights
- ➤Amylyx to present Phase 3 LUCIDITY avexitide results at ObesityWeek on November 15, 2026
- ➤LUCIDITY enrolled 78 participants across 21 U.S. sites after RYGB surgery
- ➤Avexitide targets post-bariatric hypoglycemia, a condition affecting approximately 160,000 U.S. patients
- ➤FDA has granted avexitide Breakthrough Therapy Designation for PBH and congenital hyperinsulinism
Expert Statements
Marilyn Tan, MD, FACE, FACP; Principal Investigator of the LUCIDITY clinical trial and Clinical Professor of Medicine at Stanford University School of Medicine
“”
Zeb Saeed, MD; LUCIDITY clinical trial Investigator and Associate Physician at Brigham and Women’s Hospital
“”
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that it will host an investor event at the ObesityWeek® Annual Meeting on November 15, 2026, at 11:45 a.m. ET, both in-person and virtually. The event will feature Key Opinion Leader (KOL) perspectives on the substantial burden of post-bariatric hypoglycemia (PBH). Additionally, speakers will review the results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery, which will be presented at ObesityWeek.
Get started
Create a free account to read the full story.